Intracranial extramedullary relapse of acute myeloid leukemia presenting as myeloid sarcoma mimicking meningioma: a case report and literature review
Authors:
Open Access
- 10 July 2026
- journal article
- case report
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1769002
Abstract
Background: Myeloid sarcoma (MS) is a rare extramedullary tumor of immature myeloid cells. Intracranial MS occurring as an extramedullary relapse without concurrent systemic acute myeloid leukemia (AML), is exceptionally rare and poses a considerable diagnostic challenge due to its non-specific clinical and radiological features, often mimicking more common intracranial neoplasms like meningioma. Case presentation: We report a case of isolated intracranial MS in a 61-year-old female with a prior history of FLT3-ITD mutated AML (M2), who had been in sustained complete hematologic remission for four years. She presented with a two-week history of diminished responsiveness and apathy. Cranial MRI revealed a well-defined, homogenously enhancing left frontal mass with a dural tail sign and significant peritumoral edema, initially suggestive of a meningioma. However, diffusion-weighted imaging (DWI) demonstrated restricted diffusion. The tumor was resected. Histopathological examination revealed diffuse sheets of immature myeloid cells. Immunohistochemistry was positive for CD117, CD34, and CD68, with weak MPO expression, confirming the diagnosis of MS. Post-operatively, the patient was referred for systemic chemotherapy. Conclusion: This case illustrates that intracranial MS can be a form of extramedullary relapse in AML patients even during long-term remission and can closely mimic a meningioma radiologically. Key diagnostic clues include a prior history of AML and radiographic features such as restricted diffusion on DWI and prominent peritumoral edema. However, these findings are non-specific, and a definitive diagnosis relies on histopathological and immunohistochemical analysis. The management of MS should be based on systemic AML therapy principles rather than surgery alone. This report highlights the necessity of considering MS in the differential diagnosis of new intracranial masses in patients with a history of AML to ensure timely and appropriate treatment.Keywords
This publication has 35 references indexed in Scilit:
- Myeloid Sarcoma: Presentation, Diagnosis, and TreatmentClinical Lymphoma Myeloma and Leukemia, 2017
- Acute Lymphoblastic Leukemia2011
- Pathological classification and molecular genetics of meningiomasJournal of Neuro-Oncology, 2010
- Requirement for CD44 in homing and engraftment of BCR-ABL–expressing leukemic stem cellsNature Medicine, 2006
- Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcomeLeukemia Research, 2004
- Granulocytic Sarcoma2004
- The role of FLT3 in haematopoietic malignanciesNature Reviews Cancer, 2003
- Comparison in treatments of nonleukemic granulocytic sarcomaCancer, 2002
- Granulocytic sarcoma: A clinicopathologic study of 61 biopsied casesCancer, 1981
- Autopsy study of granulocytic sarcoma (chloroma) in patients with myelogenous leukemia, hiroshima-nagasaki 1949-1969Cancer, 1973